Elenagen
Solid Tumors (e.g., Melanoma, Breast, Ovarian, Lung, Renal Cancers)
Phase 2Active
Key Facts
Indication
Solid Tumors (e.g., Melanoma, Breast, Ovarian, Lung, Renal Cancers)
Phase
Phase 2
Status
Active
Company
About CureLab Oncology
CureLab Oncology is a private, clinical-stage biotech developing Elenagen, a plasmid DNA therapy encoding the p62/SQSTM1 gene, designed to modulate the tumor microenvironment and enhance anti-cancer immunity. The company has successfully completed an international Phase I/IIa trial demonstrating safety and preliminary efficacy, and is now advancing into Phase II studies both outside and within the US. With a seasoned leadership team, CureLab is positioning its platform as a potential combination therapy to improve outcomes for patients with solid tumors.
View full company profile